Mastocytosis Registry (of Zurich)

Genetic, Multiomic and Cytokine-based Mapping of Patients With Mastocytosis/Hypertryptasemia at the University Hospital of Zurich German: Mastozytose-Register: Datenerfassung Und Weiterverwendung Von Biologischem Material Von Patienten Mit Mastozytose, Welche am Universitätsspital Zürich Behandelt Werden

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06466889

Acronym

MastoR

Enrollment

400

Registered

2024-06-20

Start date

2024-06-06

Completion date

2035-12-31

Last updated

2024-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertryptasemia, Mastocytosis

Keywords

mast cell disease

Brief summary

The study aims to summarize patients with mastocytosis and hypertryptasämia (without underlying mastocytosis or no bone marrow biopsy) in relation to demographic information, clinical progress and treatment courses. Biologic samples are collected from available routine diagnostics (serum, skin tissue, gut mucosa, bone marrow, and others) for further use in experimental research.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Adult patients with mastocytsis/hypertryptasemia which are treated at the university hospital of Zurich * available informed consent

Exclusion criteria

* denied consent

Design outcomes

Primary

Measure	Time frame	Description
Demographics	2010-2025	In the registry we collect patient's demographic data e.g. age, gender, comorbidities, smoking, preexisting atopic disease and other to look for associations to mast cell diseases.
Disease progression	2010-2025	Patients will followed up over time to get more insight in disease progression.If there is progression detected (e.g. cutaneous mastocytosis to systemic mastocytosis or ISM to advanced forms) those cases will be carefully looked at to identify triggering factors and biomarkers.

Countries

Switzerland

Contacts

Primary ContactClaudia Lang, MD

claudia.lang@usz.ch+41442551111

Outcome results